S'abonner

A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis - 27/02/13

Doi : 10.1016/j.jaci.2012.11.053 
Emma L. Beckett, B Biomed Sci a, , Richard L. Stevens, PhD b, c, , Andrew G. Jarnicki, PhD a, , Richard Y. Kim, B Biomed Sci a, Irwan Hanish, BSc a, Nicole G. Hansbro, PhD a, Andrew Deane, BSc a, Simon Keely, PhD a, Jay C. Horvat, PhD a, Ming Yang, MD, PhD a, Brian G. Oliver, PhD d, Nico van Rooijen, PhD e, Mark D. Inman, MD, PhD f, Roberto Adachi, MD g, Roy J. Soberman, MD b, h, Sahar Hamadi c, Peter A. Wark, MD, PhD a, i, Paul S. Foster, PhD a, Philip M. Hansbro, PhD a,
a Priority Research Centre for Asthma and Respiratory Disease and Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia 
b Department of Medicine, Harvard Medical School, Boston, Mass 
c Brigham and Women’s Hospital, Boston, Mass 
d Sydney Medical School and Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia 
e Department of Molecular Cell Biology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands 
f Firestone Institute for Respiratory Health, St Joseph’s Healthcare, Hamilton, Ontario, Canada 
g Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Tex 
h Massachusetts General Hospital, Boston, Mass 
i Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia 

Corresponding author: Philip M. Hansbro, PhD, Priority Research Centre for Asthma and Respiratory Disease and Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW 2308, Australia.

Abstract

Background

Cigarette smoke–induced chronic obstructive pulmonary disease (COPD) is a life-threatening inflammatory disorder of the lung. The development of effective therapies for COPD has been hampered by the lack of an animal model that mimics the human disease in a short timeframe.

Objectives

We sought to create an early-onset mouse model of cigarette smoke–induced COPD that develops the hallmark features of the human condition in a short time-frame. We also sought to use this model to better understand pathogenesis and the roles of macrophages and mast cells (MCs) in patients with COPD.

Methods

Tightly controlled amounts of cigarette smoke were delivered to the airways of mice, and the development of the pathologic features of COPD was assessed. The roles of macrophages and MC tryptase in pathogenesis were evaluated by using depletion and in vitro studies and MC protease 6–deficient mice.

Results

After just 8 weeks of smoke exposure, wild-type mice had chronic inflammation, mucus hypersecretion, airway remodeling, emphysema, and reduced lung function. These characteristic features of COPD were glucocorticoid resistant and did not spontaneously resolve. Systemic effects on skeletal muscle and the heart and increased susceptibility to respiratory tract infections also were observed. Macrophages and tryptase-expressing MCs were required for the development of COPD. Recombinant MC tryptase induced proinflammatory responses from cultured macrophages.

Conclusion

A short-term mouse model of cigarette smoke–induced COPD was developed in which the characteristic features of the disease were induced more rapidly than in existing models. The model can be used to better understand COPD pathogenesis, and we show a requirement for macrophages and tryptase-expressing MCs.

Le texte complet de cet article est disponible en PDF.

Key words : Cigarette smoke, chronic obstructive pulmonary disease, inflammation, emphysema, airway remodeling, lung function, macrophage, mast cell, protease, mouse mast cell protease 6, htryptase-β

Abbreviations used : B6, BALF, COPD, FEV100, FRC, FVC, htryptase-β, MC, mMCP, qPCR, TLC, WT


Plan


 Supported by grants from the National Health and Medical Research Council of Australia (510762, 569219, 1003565, 1003593, and 1023131), the US National Institutes of Health (AI065858 and AI059746), and the Harvard Club of Australia Foundation.
 Disclosure of potential conflict of interest: R. L. Stevens has been supported by one or more grants from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.


© 2013  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131 - N° 3

P. 752 - mars 2013 Retour au numéro
Article précédent Article précédent
  • Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease
  • Maxie Kohler, AnnSofi Sandberg, Sanela Kjellqvist, Andreas Thomas, Reza Karimi, Sven Nyrén, Anders Eklund, Mario Thevis, C. Magnus Sköld, Åsa M. Wheelock
| Article suivant Article suivant
  • Effect of montelukast for treatment of asthma in cigarette smokers
  • David Price, Todor A. Popov, Leif Bjermer, Susan Lu, Romana Petrovic, Kristel Vandormael, Anish Mehta, Jolanta D. Strus, Peter G. Polos, George Philip

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.